Gilead Sciences raked in nearly $900M from COVID-19 drug remdesivir

Gilead Sciences sold nearly $900 million worth of its coronavirus treatment remdesivir from July to September, the company announced this week. The California-based drugmaker on Wednesday reported third-quarter revenues of $873 million from its antiviral drug, which was the first COVID-19 treatment to be fully approved by the US Food and Drug Administration. The drug,… Read More on New York Post